Back to search

Trio Medicines Limited

05616306

active
Private Limited Company
england wales
Companies House
Health Score
75 / 100

Some Concerns

25/30
Filing
10/30
Financial
40/40
Risk
  • No accounts filed in last 18 months (-5)
  • Going concern doubt noted in accounts (-10)

Details

PAVILION VIEW, 19 NEW ROAD, EAST SUSSEX, BN1 1EY
Incorporated 08/11/2005

Compliance

Last accounts

31/01/2025

small

Next accounts due

31/10/2026

On track

Confirmation statement

Last: 17/11/2025

Due 01/12/2026

On track

Industry

86900
Other human health activities

Officers

Dr Malcolm James Boyce

director · Since 08/11/2005

DOCTOR

BRITISH · UNITED KINGDOM · Age 87

Also on 5 other boards

Dr Steven John Warrington

director · Since 08/11/2005

DOCTOR

BRITISH · ENGLAND · Age 79

Persons with Significant Control

Dr Malcolm James Boyce

75–100% shares
75–100% votes

British · United Kingdom · Age 87

143 Holland Road, London, W14 8AS

Notified 17/11/2025

Former PSCs

Hammersmith Medicines Research Limited

Ceased 17/11/2025

CompanyRankvs 10182+ SIC 86900 peers
60

Financial strength100th percentile among SIC peers · 25/25
Employees85th percentile among SIC peers · 13/15
LiquidityCurrent ratio 0.02× · 2/20
Longevity15 years trading (max 15) · 15/15
Filing complianceAll filings up to date · 15/15
Going concern doubt -10
Show leaderboard
How is this score calculated?
Financial strength25/25 pts

Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.

Employees13/15 pts

Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.

Liquidity2/20 pts

Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.

Longevity15/15 pts

One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.

Filing compliance15/15 pts

Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.

Risk deductions

Going concern doubt: -10 pts

Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.

Going Concern Doubt

the withdrawal of of the substantial funding previously received from Hammersmith Medicines Research Limited, there exists a material uncertainty regarding the company's ability to continue as a going concern. 1.3 Research and development expenditure Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the e

Key FinancialsYear ending 31/01/2025

Net Worth

£14.8M

Balance sheet strength

Cash

£21k

Cash in the bank

Net Current Assets

-£2.9M

Working capital

Current Assets

£67k

Current Liabilities

£3.0M

Debtors

£46k

Admin Expenses

£885k

3avg. employees+3
Prepared with CCH Software

EstimatesDerived

YearCurrent RatioImplied Profit
20250.02+£0
20240.06+£0
20230.21

Derived from filed accounts. Not audited figures.